Telit Comms taps into GPS market with US acquisition
Machine-to-machine (M2M) wireless tech firm Telit Communications is to buy GPS modules and solutions group Navman Wireless OEM Solutions for $3m in cash.
Machine-to-machine (M2M) wireless tech firm Telit Communications is to buy GPS modules and solutions group Navman Wireless OEM Solutions for $3m in cash.
"The acquisition of Navman's technology and its US-based executive engineering and sales staff will make Telit a major contender in the GPS market while providing an enhanced product portfolio for its M2M customers," Telit said.
Telit hopes to take advantage of the potential within the GPS market in the coming years, with global shipments of GPS devices expected to grow at a compounded annual growth rate of at least 20% until 2013. According to RNCOS, shipments will reach 900m units by 2013, generating more than $70bn in annual revenue.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Navman's reputation for delivering state-of-the-art GPS technology and the global reach of Telit's sales and marketing organization put us in a strong position to benefit from the growth in the GPS sector," said Telit's Chief Executive Oozi Cats.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published